The psychedelic drugs market  is moving from a research-led niche into a structured, clinic-delivered therapeutic category built around supervised dosing and psychotherapy support. Psychedelic-assisted therapies are being developed to address high-burden mental health conditions where conventional treatments often fall short—most notably treatment-resistant depression, PTSD,...